BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 25426078)

  • 1. Diabetes, pancreatic cancer, and metformin therapy.
    Gong J; Robbins LA; Lugea A; Waldron RT; Jeon CY; Pandol SJ
    Front Physiol; 2014; 5():426. PubMed ID: 25426078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
    Cifarelli V; Lashinger LM; Devlin KL; Dunlap SM; Huang J; Kaaks R; Pollak MN; Hursting SD
    Diabetes; 2015 May; 64(5):1632-42. PubMed ID: 25576058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
    Gadducci A; Biglia N; Tana R; Cosio S; Gallo M
    Crit Rev Oncol Hematol; 2016 Sep; 105():73-83. PubMed ID: 27378194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.
    Jin K; Ruan L; Pu J; Zhong A; Wang F; Tan S; Huang H; Mu J; Yang G
    Mol Cell Endocrinol; 2018 Dec; 478():53-61. PubMed ID: 30025915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling.
    Mohammed A; Janakiram NB; Brewer M; Ritchie RL; Marya A; Lightfoot S; Steele VE; Rao CV
    Transl Oncol; 2013 Dec; 6(6):649-59. PubMed ID: 24466367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
    Kato K; Iwama H; Yamashita T; Kobayashi K; Fujihara S; Fujimori T; Kamada H; Kobara H; Masaki T
    Oncol Rep; 2016 Mar; 35(3):1582-92. PubMed ID: 26708419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin influences drug sensitivity in pancreatic cancer cells.
    Candido S; Abrams SL; Steelman L; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Lombardi P; Montalto G; Cervello M; Gizak A; Rakus D; Suh PG; Libra M; McCubrey JA
    Adv Biol Regul; 2018 May; 68():13-30. PubMed ID: 29482945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro.
    Chen X; Hu C; Zhang W; Shen Y; Wang J; Hu F; Yu P
    Tumour Biol; 2015 Dec; 36(12):9873-83. PubMed ID: 26164004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
    Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
    J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
    Kato H; Sekine Y; Furuya Y; Miyazawa Y; Koike H; Suzuki K
    Biochem Biophys Res Commun; 2015 May; 461(1):115-21. PubMed ID: 25862373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin Induces Apoptosis and Inhibits Proliferation through the AMP-Activated Protein Kinase and Insulin-like Growth Factor 1 Receptor Pathways in the Bile Duct Cancer Cells.
    Lee J; Hong EM; Kim JH; Jung JH; Park SW; Koh DH; Choi MH; Jang HJ; Kae SH
    J Cancer; 2019; 10(7):1734-1744. PubMed ID: 31205529
    [No Abstract]   [Full Text] [Related]  

  • 15. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer.
    Cai D; Sun H; Qi Y; Zhao X; Feng M; Wu X
    Int J Gynecol Cancer; 2016 Nov; 26(9):1667-1672. PubMed ID: 27654259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and pancreatic cancer: Is there a role?
    De Souza A; Khawaja KI; Masud F; Saif MW
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):235-42. PubMed ID: 26740120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer
    Zhang JW; Zhao F; Sun Q
    Oncol Lett; 2018 Feb; 15(2):1811-1816. PubMed ID: 29434877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.
    Bhaw-Luximon A; Jhurry D
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2159-71. PubMed ID: 27160287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic activation of AMP-activated kinase as a strategy for slowing aging.
    McCarty MF
    Med Hypotheses; 2004; 63(2):334-9. PubMed ID: 15236799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
    Rieder S; Michalski CW; Friess H; Kleeff J
    Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.